Liver International · 2016 · 33 citations · 17 references
PharmacyInfectious DiseasesPharmacotherapyHepatitis PharmacotherapyMolecular VirologyVirologyAntiviral AgentsAntiviral PharmacotherapyAntiviral TherapyCirrhosisViral HepatitisViral Hepatitis TreatmentAdverse Drug EventsAntiviral Therapy In CirrhosisContraindications In Hepatitis PharmacotherapyHepatitis C Virus GenotypeOpen-label TrialsRibavirin TherapyRibavirin-based RegimensViral Hepatitis-related Cirrhosis
BACKGROUND: The current standard-of-care for treatment of HCV genotype 2 (GT-2) patients is the combination of sofosbuvir (SOF) with weight-based ribavirin (RBV). Patients with HCV GT-2 infection and ribavirin contraindications require the use of SOF plus NS5A inhibitor daclatasvir (DCV) which is not reimbursed everywhere. METHODS: We conducted an open-label observational, prospective study on a subgroup of GT-2 patients either naïve or treatment experienced (TE) with contraindications to the use of RBV. Patients with cirrhosis of Child-Pugh-Turcotte (CPT) class A and B or advanced fibrosis with comorbidities were included. They were assigned to receive 12 or 24 weeks of SOF/DCV. The primary end point of the study was sustained virological response (SVR) defined as HCV RNA levels <12 IU/ml, 12 weeks post treatment. RESULTS: Out of 106 patients with GT-2 who received treatment at our unit from July 2014 to June 2015, 20 (18.8%) patients, whose treatment could not be deferred, were ribavirin intolerant; 19 received SOF/DCV combination for 12 or 24 weeks. The majority of the patients was men, 58% had cirrhosis, and 58% were TE. All treated patients achieved SVR regardless of treatment duration. The most common adverse events (AEs) were fatigue, headache and nausea. No discontinuations due to AEs were observed. Two patients had oesophageal bleeding but continued treatment and achieved SVR; one patient developed HCC 12 weeks post treatment, but remained HCV RNA undetectable. CONCLUSIONS: This study supports the use of SOF/DCV for 12 weeks in non-cirrhotics or 24 weeks in cirrhotic GT-2 patients who cannot tolerate RBV, including those with decompensated disease.
17
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz, Alessandra Mangia, David Wyles et al. · New England Journal of Medicine · 2013 · 1.8K citations
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam H. Afdhal, Stefan Zeuzem, Paul Y. Kwo et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text
Global distribution and prevalence of hepatitis C virus genotypes
Jane P. Messina, Isla Humphreys, Abraham D. Flaxman et al. · Hepatology · 2014 · 1.6K citations · Full text